INVIVYD, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
INVIVYD, INC. (IVVD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.87 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-13
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-06-30 was $0.87, a 102.33% increase year-over-year.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $1.19, a 27.96% increase year-over-year.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-09-30 was $0.58, a 21.62% decline year-over-year.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $0.43, a 70.95% decline year-over-year.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $0.89, a 52.66% decline from fiscal 2024.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $1.88, a 28.77% increase from fiscal 2023.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $1.46, a 47.67% decline from fiscal 2022.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $2.79.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 4 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 7 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.87 10-Q · filed 2026-08-13 | $1.11 10-Q · filed 2026-08-13 | |||||
| 2026-03-31 | $1.19 10-Q · filed 2026-05-14 | ||||||
| 2025-12-31 | $0.89 10-K · filed 2026-03-05 | ||||||
| 2025-09-30 | $0.58 10-Q · filed 2025-11-06 | $0.86 10-Q · filed 2025-11-06 | |||||
| 2025-06-30 | $0.43 10-Q · filed 2026-08-13 | $0.90 10-Q · filed 2026-08-13 | |||||
| 2025-03-31 | $0.93 10-Q · filed 2026-05-14 | ||||||
| 2024-12-31 | $1.88 10-K · filed 2026-03-05 | ||||||
| 2024-09-30 | $0.74 10-Q · filed 2025-11-06 | $2.06 10-Q · filed 2025-11-06 | |||||
| 2024-06-30 | $1.48 10-Q · filed 2025-08-14 | $2.21 10-Q · filed 2025-08-14 | |||||
| 2024-03-31 | $2.53 10-Q · filed 2025-05-15 | ||||||
| 2023-12-31 | $1.46 10-K · filed 2025-03-20 | ||||||
| 2023-09-30 | $1.06 10-Q · filed 2024-11-14 | $1.15 10-Q · filed 2024-11-14 | |||||
| 2023-06-30 | $0.86 10-Q · filed 2024-08-14 | $1.18 10-Q · filed 2024-08-14 | |||||
| 2023-03-31 | $1.34 10-Q · filed 2024-05-09 | ||||||
| 2022-12-31 | $2.79 10-K · filed 2024-03-28 | ||||||
| 2022-09-30 | $2.28 10-Q · filed 2023-11-09 | $3.50 10-Q · filed 2023-11-09 | |||||
| 2022-06-30 | $2.07 10-Q · filed 2023-08-10 | $3.88 10-Q · filed 2023-08-10 | |||||
| 2022-03-31 | $4.23 10-Q · filed 2023-05-11 | ||||||
| 2021-12-31 | $7.56 8-K · filed 2024-02-09 | ||||||
| 2021-09-30 | $9.03 10-Q · filed 2022-11-10 | $6.51 10-Q · filed 2022-11-10 | |||||
| 2021-06-30 | $6.75 10-Q · filed 2022-08-15 | $5.96 10-Q · filed 2022-08-15 | |||||
| 2020-12-31 | $0.21 10-K · filed 2022-03-31 | ||||||
| 2020-09-30 | $0.68 10-Q · filed 2021-11-15 | $0.21 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | $0.01 10-Q · filed 2021-09-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |